Loading...
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
Vemurafenib, a selective inhibitor of oncogenic BRAF kinase carrying the V600 mutation, is approved for treatment of advanced BRAF mutation–positive melanoma. This study characterized mass balance, metabolism, rates/routes of elimination, and disposition of (14)C-labeled vemurafenib in patients with...
Saved in:
| Published in: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BlackWell Publishing Ltd
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4324687/ https://ncbi.nlm.nih.gov/pubmed/25729580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.113 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|